Table 1 (abstract O4). Characteristics of biologic initiators in the CARRA Registry
| Â | All biologic initiators N= 708 | Non switchers n=517 | Switchers n=146 | Delayed switchers n=45 | Comparison of non-switchers vs switchers P value |
|---|---|---|---|---|---|
Age (years) median, range, IQR | 10 (IQR 6, 13) | 10 (6, 13) | 10.5 (8, 14) | 8 (4, 11) | ns |
Sex (F) n, % | 547 (77%) | 388 (75%) | 119 (82%) | 40 (89%) | <0.05 |
Race: n, % | Â | Â | Â | Â | Â |
White | 582 (82%) | 427 (83%) | 117 (80%) | 38 (84%) | ns |
Black | 27 (4%) | 19 (4%) | 5 (3%) | 3 (7%) | ns |
Asian | 29 (4%) | 17 (3%) | 9 (6%) | 3 (7%) | ns |
Hispanic, Latino | 68 (10%) | 55 (10%) | 11 (8%) | 2 (4%) | ns |
Other | 13 (2%) | 7 (1%) | 5 (3%) | 1 (2%) | ns |
JIA subtype: n, % | Â | Â | Â | Â | ns |
 RF+ poly | 90 (13%) | 69 (13%) | 16 (11%) | 5 (11%) |  |
 RF- poly | 376 (53%) | 278 (54%) | 71 (49%) | 27 (60%) |  |
 Persistent Oligo | 66 (10%) | 51 (10%) | 11 (8%) | 4 (9%) |  |
Extended oligo | 44 (6%) | 32 (6%) | 10 (7%) | 2 (4%) | Â |
 ERA | 72 (10%) | 49 (10%) | 21 (14%) | 2 (4%) |  |
 psoriatic | 44 (6%) | 27 (5%) | 14 (10%) | 3 (7%) |  |
undifferentiated | 15 (2%) | 10 (2%) | 3 (2%) | 2 (4%) | Â |
Uveitis n, % | 48 (7%) | 35 (7%) | 9 (6%) | 4 (9%) | ns |
IBD n, % | 18 (3%) | 14 (3%) | 3 (2%) | 1 (2%) | ns |
Time from diagnosis to start biologic (days) median, range, IQR | 217 (66-1126) | 218 (70, 1113) | 209 (54, 1211) | 217 (75, 927) | ns |
Time from disease onset to diagnosis (days, median, IQR) | 119 (48-298) | 119 (47, 305) | 118 (44, 278) | 135 (52, 232) | ns |
MTX use (all) n, % | 554 (78%) | 394 (76%) | 119 (82%) | 41 (91%) | <0.05 |
PO MTX n, % | 249 (35%) | 186 (36%) | 45 (31%) | 18 (40%) | ns |
SQ MTX n, % | 389 (55%) | 272 (53%) | 87 (60%) | 30 (67%) | ns |
sulfasalazine use n, % | 36 (5%) | 25 (5%) | 8 (5%) | 3 (7%) | ns |
Leflunomide use n, % | 16 (2%) | 12 (2%) | 3 (2%) | 1 (2%) | ns |
Calendar year of biologic start: median, IQR | 2014 (2012-2015) | 2014 (2013, 2015) | 2014 (2012, 2015) | 2012 (2010, 2014) | <0.05 |
Medication starting: n, % | Â | Â | Â | Â | ns |
TNF (all) | Â | Â | Â | Â | Â |
 etanercept | 476 (67%) | 336 (65%) | 103 (71%) | 37(82%) |  |
 adalimumab | 152 (21%) | 118 (23%) | 29 (20%) | 5 (11%) |  |
 infliximab | 36 (5%) | 30 (6%) | 3 (2%) | 3 (7%) |  |
 golimumab | 3 (0.4%) | 2 (0.4%) | 1 (0.7%) | 0 |  |
 certolizumab | 3 (0.4%) | 3 (0.6%) | 0 | 0 |  |
Non TNF (all) | Â | Â | Â | Â | Â |
 tocilizumab | 14 (2%) | 12 (2%) | 2 (1%) | 0 |  |
 abatacept | 17 (2%) | 11 (2%) | 6 (4%) | 0 |  |
 rituximab | 3 (0.4%) | 3 (0.6%) | 0 | 0 |  |
 ustekinumab | 0 | 0 | 0 | 0 |  |
 anakinra | 3 (0.4%) | 1 (0.2%) | 2 (1%) | 0 |  |
 canakinumab | 1 (0.1%) | 1 (0.2%) | 0 | 0 |  |